| 摘要 |
<p>Compounds and pharmaceutically acceptable salts of formula I wherein, R1 is C1-4 alkoxy optionally substituted by one or more fluorine atoms, R2 is H or C1-4 alkoxy optionally substituted by one or more fluorine atoms, R3 is a 5 or 6 membered heterocyclic ring containing at least one heteroatom selected from N, 0 and S, the ring being optionally substituted by one or more groups selected from halogen, C1-4 alkoxy, C1-4 alkyl and CF3, R4 is a 4, 5, 6, or 7 membered heterocyclic ring containing at least one heteroatom selected from N, 0 and S, the ring being optionally fused to a benzene ring or a 5 or 6 membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring system as a whole being optionally substituted by one or more groups independently selected from OH, C1-4 alkyl, C1-4 alkoxy, halogen, CONR8R9, SO2NR8R9, (CH2)bNR8R9 and NHSO2(C1-4 alkyl), and when S is a member of the ring system, it may be substituted by one or two oxygen atoms, R8 and R9 independently represent H or C1-4 alkyl, or together with the N atom to which they are attached they may represent a 5 or 6 membered heterocyclic ring containing at least one heteroatom selected from N, 0 and S, b is 0, 1,2 or 3, X is CH or N and L is absent or represents a cyclic group of formula Ia wherein, N is attached to the 2-position of the quinoline or quinazoline ring, A is absent or represents CO or SO2-, Z is CH or N, m is 1 or 2, and in addition, when Z represents CH, it may represent 0, n is 1, 2 or 3, provided that the sum of m and n is 2, 3, 4 or 5, or n is a chain of formula Ib wherein, N is attached to the 2-position of the quinoline or quinazoline ring, A' and Z' are the same as A and Z above, R6 and R7 independently represent H or C1-4 alkyl, p is 1, 2 or 3, and in addition, when Z' represents CH, it may represent 0. Also described is a method of manufacturing these compounds and the use of these compounds as medicaments for the treatment of benign prostatic hyperplasia.</p> |
